27,200 Shares in Corcept Therapeutics Incorporated $CORT Bought by OMERS ADMINISTRATION Corp

OMERS ADMINISTRATION Corp bought a new stake in Corcept Therapeutics Incorporated (NASDAQ:CORT) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 27,200 shares of the biotechnology company’s stock, valued at approximately $1,096,000.

A number of other hedge funds and other institutional investors also recently bought and sold shares of CORT. First Trust Advisors LP lifted its holdings in Corcept Therapeutics by 213.5% during the 1st quarter. First Trust Advisors LP now owns 2,173,376 shares of the biotechnology company’s stock worth $87,609,000 after buying an additional 1,480,059 shares during the last quarter. AQR Capital Management LLC increased its holdings in shares of Corcept Therapeutics by 546.9% in the 3rd quarter. AQR Capital Management LLC now owns 1,507,209 shares of the biotechnology company’s stock valued at $125,264,000 after acquiring an additional 1,274,215 shares during the last quarter. Geode Capital Management LLC raised its position in shares of Corcept Therapeutics by 38.0% during the 4th quarter. Geode Capital Management LLC now owns 2,668,918 shares of the biotechnology company’s stock worth $92,892,000 after acquiring an additional 734,646 shares in the last quarter. Norges Bank purchased a new stake in Corcept Therapeutics during the fourth quarter worth approximately $24,213,000. Finally, UBS Group AG lifted its stake in Corcept Therapeutics by 413.8% during the third quarter. UBS Group AG now owns 549,938 shares of the biotechnology company’s stock worth $45,705,000 after purchasing an additional 442,898 shares during the last quarter. 93.61% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several brokerages have commented on CORT. Canaccord Genuity Group increased their price target on shares of Corcept Therapeutics from $135.00 to $150.00 and gave the company a “buy” rating in a research note on Wednesday. Zacks Research upgraded shares of Corcept Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Monday, May 4th. Wolfe Research cut shares of Corcept Therapeutics from a “peer perform” rating to an “underperform” rating and set a $50.00 target price for the company. in a report on Monday. Piper Sandler reiterated an “overweight” rating and set a $165.00 price target (up from $88.00) on shares of Corcept Therapeutics in a research note on Thursday. Finally, Weiss Ratings reissued a “hold (c-)” rating on shares of Corcept Therapeutics in a research report on Wednesday, June 24th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $119.17.

Corcept Therapeutics Price Performance

Shares of Corcept Therapeutics stock opened at $118.32 on Friday. The firm’s fifty day simple moving average is $83.68 and its 200-day simple moving average is $56.37. The stock has a market capitalization of $12.70 billion, a price-to-earnings ratio of 281.72 and a beta of 0.47. Corcept Therapeutics Incorporated has a 12 month low of $28.66 and a 12 month high of $122.21.

Corcept Therapeutics (NASDAQ:CORT) last issued its quarterly earnings results on Wednesday, July 29th. The biotechnology company reported $0.36 earnings per share for the quarter, topping analysts’ consensus estimates of $0.02 by $0.34. Corcept Therapeutics had a net margin of 6.52% and a return on equity of 8.48%. The firm had revenue of $256.15 million during the quarter, compared to analysts’ expectations of $221.15 million. During the same quarter in the prior year, the business earned $0.29 EPS. Corcept Therapeutics’s quarterly revenue was up 31.7% compared to the same quarter last year. Analysts anticipate that Corcept Therapeutics Incorporated will post 0.53 earnings per share for the current year.

Key Headlines Impacting Corcept Therapeutics

Here are the key news stories impacting Corcept Therapeutics this week:

• Positive Sentiment: Strong Q2 performance: Corcept reported adjusted earnings of $0.36 per share, well above the $0.02 consensus estimate, while revenue rose 31.7% year over year to $256.1 million, exceeding expectations of approximately $221.2 million. Operating profit increased 54.8% to $41.3 million. Corcept second-quarter financial results
• Positive Sentiment: Higher 2026 outlook: Management raised its full-year revenue forecast to $1.1 billion-$1.2 billion, above the roughly $1.0 billion analyst consensus. The increase reflects continued Korlym growth and a strong launch for Lifyorli. CORT Q2 earnings and raised outlook
• Positive Sentiment: Analyst price-target increase: Piper Sandler reaffirmed its “overweight” rating and raised its price target to $165 from $88, signaling substantially greater confidence in Corcept’s growth prospects. Piper Sandler Corcept rating
• Neutral Sentiment: Financial position: Corcept ended the quarter with $111.0 million in cash and equivalents and generated $33.5 million in operating cash flow, providing resources to support commercialization and development activities.
• Neutral Sentiment: Mixed ownership signals: Institutional activity was balanced, with 189 investors increasing positions and 194 reducing them during the latest reporting period.
• Negative Sentiment: Insider selling and valuation risk: Recent insider activity was heavily weighted toward sales, including transactions by senior executives. Following the rally, the stock also trades at a very elevated valuation, which could increase sensitivity to any slowdown in growth or execution issues.
• Negative Sentiment: Contrasting analyst view: Wolfe Research recently downgraded Corcept to “underperform,” highlighting that not all analysts share the bullish outlook. Wolfe Research downgrade

Insiders Place Their Bets

In other news, Director David L. Mahoney sold 20,000 shares of the stock in a transaction dated Wednesday, June 17th. The shares were sold at an average price of $84.53, for a total transaction of $1,690,600.00. Following the completion of the sale, the director owned 26,147 shares in the company, valued at approximately $2,210,205.91. This represents a 43.34% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Atabak Mokari sold 40,000 shares of the firm’s stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $81.15, for a total value of $3,246,000.00. Following the transaction, the chief financial officer directly owned 16,130 shares in the company, valued at approximately $1,308,949.50. This represents a 71.26% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 300,000 shares of company stock valued at $22,088,050. 20.70% of the stock is owned by insiders.

Corcept Therapeutics Company Profile

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.